Unmasking New Solutions for OSA

By : Krishna Anindyo | Wednesday, May 20 2020 - 16:43 IWST

Danny Eckert sleep lab
Danny Eckert sleep lab

INDUSTRY co.idOSA, or repetitive upper airway closure during sleep that restricts breathing and is usually accompanied by snoring, has major adverse health, safety and economic impact. Even with established interventions such as continuous positive airway pressure (CPAP), these problems might not resolve.

 

Nearly 1 billion people globally, including 1 million Australians, have obstructive sleep apnoea (OSA) and more targeted treatments are ‘urgently needed’ to reduce the costs and health impacts, say Flinders University experts.

To find better, more effective, individually targeted treatments for people with OSA, Australian Federal Government funding of more than $2 million has been awarded to Flinders University’s Adelaide Institute for Sleep Health.

National Health and Medical Research Council Investigator Leadership grant awardee and Adelaide Institute for Sleep Health Director, Professor Danny Eckert, says a range of issues means OSA is often untreated, and more than 50% of people cannot tolerate long-term use of the main treatment, CPAP.

 

In all, sleep disorders and inadequate sleep cost Australia more than $65 billion per year, and sleep apnoea is the most common, says Matthew Flinders Fellow Professor Eckert.

&ldquo New treatments are urgently needed, and we’re aiming to use and develop novel approaches to identify the causes of OSA on a per patient basis, improve current therapies and management approaches and test if new targeted therapies can be used to treat OSA,” he says. Wednesday (5/20/2020).

“Current diagnosis, treatment and management of OSA are imprecise, are cumbersome, time-consuming, costly and are failing too often because they don’t take into account the differences in the ways people get OSA and the different ways it can present.”

Professor Eckert says his long-running research work takes a four-pronged approach to achieve much-needed improvement in this area of medicine, to Understand the different underlying causes of OSA to identify targets for therapy for each patient, Develop simplified yet more informative clinical tools to fast-track the diagnosis process and inform suitable, targeted treatment solutions for individual patients, Improve existing non-CPAP treatments such as dental devices and develop new drug interventions, Test the efficiency of new therapies, including combination therapies, to treat OSA.

OSA is the most common breathing related sleep disorder, restricting breathing to cause low oxygen levels (hypoxemia) and sleep disruption.

Untreated OSA increases the risk for heart disease and metabolic disorders such as diabetes, impaired cognitive function, cancer, depression, sleepiness, motor vehicle accidents and injury, and all-cause mortality.

News Comment

Today's Industry

OSSRA (Photo by Synopsys)

Selasa, 26 Mei 2020 - 12:15 WIB

Key Findings from The OSSRA 2020 Report

Our 2020 OSSRA infographic shows key findings and open source trends from the Synopsys Open Source Security and Risk Analysis report

HIMA (Photo by Rail Solutions Asia 2019 - German Pavilion)

Selasa, 26 Mei 2020 - 11:34 WIB

HIMA Empowers Industrial and Hazardous Installations with Remote Maintenance to Provide Smart Safety and Cybersecurity

The HIMA Group introduced a solution for remote maintenance in the industrial context, living up to the standards set by the HIMA Smart Safety Platform (SSP), the world’s first scalable safety…

PropertyGuru (Photo by PropertyGuru-Brand-Refresh-New-Logo-2 Digital Market Asia)

Kamis, 21 Mei 2020 - 08:39 WIB

PropertyGuru Beats Prospectus Forecast In 2019 and Delivers 24% Revenue Growth

PropertyGuru Group, Southeast Asia‟s leading property technology (“PropTech”) company, announces its results for the financial year ending 31 December 2019. The Group has beaten its prospectus…

Veolia Water Technologies

Kamis, 21 Mei 2020 - 08:09 WIB

Veolia Water Technologies Paves The Way for Soluble Fertilizer Revolution in Australia

Perth-based Salt Lake Potash Ltd. is developing the Lake Way potash mining project to produce 245,000 tons per year of SOP (K2SO4) from dry salt lake deposits in the Northern Goldfields region…

Naresh Desai, Vice President, Specialist Business, Asia Pacific, at Tech Data

Kamis, 21 Mei 2020 - 07:34 WIB

Tech Data Partners with Dataiku to Accelerate Enterprise AI Adoption

Tech Data (Nasdaq: TECD) announced it has partnered with Dataiku, one of the world's leading enterprise artificial intelligence (AI) and machine learning platforms. As a catalyst for data-powered…